OBJECTIVE: To determine whether actively using, methamphetamine (meth)-dependent men who have sex with men (msm) could be enrolled and retained in a pharmacologic intervention trial, and the degree to which participants would adhere to study procedures, including medication adherence. study design: phase ii randomized, double-blind trial of bupropion vs. placebo. METHODS:Thirty meth-dependent, sexually active MSM were randomized to receive daily bupropion XL 300 mg or placebo for 12 weeks. Participants received weekly substance use counseling, provided weekly urine specimens, and completed monthly audio-computer assisted self-interview (ACASI) behavioral risk assessments. Adherence was measured by medication event monitoring systems (MEMS) caps (the number of distinct MEMS cap openings divided by the number of expected doses) and self-report. RESULTS:Ninety percent completed the trial: 89% of monthly ACASIs were completed, 81% of study visits were attended, and 81% of urine samples were collected. Adherence by MEMS cap was 60% and by self-report was 81% and did not differ significantly by treatment assignment. The median number of positive urine samples was 5.5 out of a possible 11 (50%). Participants in both arms reported similar declines in the median number of sex partners (P = 0.52). No serious adverse events occurred and there were no significant differences in adverse events by treatment assignment (P = 0.11). CONCLUSIONS: It is feasible to enroll and retain actively using, meth-dependent MSM in a pharmacologic intervention. Bupropion was well tolerated. Study participation and retention rates were high, however, study drug medication adherence was only moderate. Findings support a larger trial with improved adherence support to evaluate the efficacy of bupropion and other pharmacologic interventions for meth dependence in this population.
RCT Entities:
OBJECTIVE: To determine whether actively using, methamphetamine (meth)-dependent men who have sex with men (msm) could be enrolled and retained in a pharmacologic intervention trial, and the degree to which participants would adhere to study procedures, including medication adherence. study design: phase ii randomized, double-blind trial of bupropion vs. placebo. METHODS: Thirty meth-dependent, sexually active MSM were randomized to receive daily bupropion XL 300 mg or placebo for 12 weeks. Participants received weekly substance use counseling, provided weekly urine specimens, and completed monthly audio-computer assisted self-interview (ACASI) behavioral risk assessments. Adherence was measured by medication event monitoring systems (MEMS) caps (the number of distinct MEMS cap openings divided by the number of expected doses) and self-report. RESULTS: Ninety percent completed the trial: 89% of monthly ACASIs were completed, 81% of study visits were attended, and 81% of urine samples were collected. Adherence by MEMS cap was 60% and by self-report was 81% and did not differ significantly by treatment assignment. The median number of positive urine samples was 5.5 out of a possible 11 (50%). Participants in both arms reported similar declines in the median number of sex partners (P = 0.52). No serious adverse events occurred and there were no significant differences in adverse events by treatment assignment (P = 0.11). CONCLUSIONS: It is feasible to enroll and retain actively using, meth-dependent MSM in a pharmacologic intervention. Bupropion was well tolerated. Study participation and retention rates were high, however, study drug medication adherence was only moderate. Findings support a larger trial with improved adherence support to evaluate the efficacy of bupropion and other pharmacologic interventions for meth dependence in this population.
Authors: S O Aral; J P Hughes; B Stoner; W Whittington; H H Handsfield; R M Anderson; K K Holmes Journal: Am J Public Health Date: 1999-06 Impact factor: 9.308
Authors: Steven Shoptaw; Cathy J Reback; James A Peck; Xiaowei Yang; Erin Rotheram-Fuller; Sherry Larkins; Rosemary C Veniegas; Thomas E Freese; Christopher Hucks-Ortiz Journal: Drug Alcohol Depend Date: 2004-11-28 Impact factor: 4.492
Authors: Margaret A Chesney; Beryl A Koblin; Patrick J Barresi; Marla J Husnik; Connie L Celum; Grant Colfax; Kenneth Mayer; David McKirnan; Franklyn N Judson; Yijian Huang; Thomas J Coates Journal: Am J Public Health Date: 2003-06 Impact factor: 9.308
Authors: Hanne Thiede; Richard A Jenkins; James W Carey; Rebecca Hutcheson; Katherine K Thomas; Ronald D Stall; Edward White; Iris Allen; Roberto Mejia; Matthew R Golden Journal: Am J Public Health Date: 2008-04-29 Impact factor: 9.308
Authors: Keith A Hermanstyne; Glenn-Milo Santos; Eric Vittinghoff; Deirdre Santos; Grant Colfax; Phillip Coffin Journal: Drug Alcohol Depend Date: 2014-08-05 Impact factor: 4.492
Authors: Phillip O Coffin; Glenn-Milo Santos; Jaclyn Hern; Eric Vittinghoff; Deirdre Santos; Tim Matheson; Grant Colfax; Steven L Batki Journal: Addiction Date: 2017-08-29 Impact factor: 6.526
Authors: Glenn-Milo Santos; Phillip Coffin; Deirdre Santos; Shannon Huffaker; Tim Matheson; Jason Euren; Anna DeMartini; Christopher Rowe; Judith A Hahn; David Vlahov; Eric Vittinghoff; Steven L Batki Journal: J Acquir Immune Defic Syndr Date: 2016-05-01 Impact factor: 3.731
Authors: Jeremy D Kidd; Margaret M Paschen-Wolff; Amy A Mericle; Billy A Caceres; Laurie A Drabble; Tonda L Hughes Journal: J Subst Abuse Treat Date: 2021-06-16